Producer
Grifols
Second-largest plasma company globally; operates 400+ plasma collection centers worldwide; processes ~25% of global plasma supply; investing EUR 160M in Barcelona fractionation expansion (2025); major US presence through Talecris acquisition
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Grifols supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Grifols makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Biopharma (Plasma-Derived Proteins)
70%Diagnostic Division
15%Bio Supplies + Hospital
15%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Grifols is publicly known as a plasma protein manufacturer, but their Diagnostic division (Procleix NAT testing) makes the nucleic acid testing (NAT) systems used in blood banks globally to screen donated blood and plasma for HIV, hepatitis C, and hepatitis B. The same Grifols system that tests every unit of donated blood at a US hospital blood bank also screens plasma at Grifols' own Biomat USA donation centers before fractionation. Grifols is simultaneously the manufacturer of therapeutic plasma proteins AND the maker of the safety testing systems that ensure those proteins and all blood transfusions are safe. This vertical integration means Grifols sets both the standard for what constitutes safe plasma (through their diagnostic systems) and is a major buyer of plasma that meets that standard (through their fractionation). The 2021 FDA investigation of Grifols Los Angeles plasma center for record-keeping lapses highlighted that when a dominant plasma company also controls the testing infrastructure, quality failures have downstream systemic effects.
Grifols S.A. ↗Origin2023
Grifols was founded by Dr. Josep Antoni Grifols Roig, a Spanish hematologist who established Spain's first blood bank at the Hospital of the Holy Cross and Saint Paul in Barcelona in 1940 — during the aftermath of the Spanish Civil War, when blood banking was a survival necessity. He invented a citrate-glucose-saline (CGS) solution for storing donated blood and pioneered transfusion medicine in Spain. The Grifols family has operated the company for three generations. The transition from blood banking to plasma fractionation happened in the 1950s-60s as Grifols moved from collecting blood to collecting and processing the plasma component for higher-value therapeutic proteins. Their 2011 acquisition of Talecris Biotherapeutics (US, $3.4B) made them the second-largest global plasma company. A Spanish hematologist's wartime blood bank became a global pharmaceutical company by following the value chain from whole blood to therapeutic plasma proteins over 80 years.
Grifols S.A. ↗